GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Intrinsic Value: Projected FCF

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Intrinsic Value: Projected FCF : $0.00 (As of May. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-25), Advanced Proteome Therapeutics's Intrinsic Value: Projected FCF is $0.00. The stock price of Advanced Proteome Therapeutics is $0.0002. Therefore, Advanced Proteome Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Advanced Proteome Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

APTCF's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.31
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Advanced Proteome Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for Advanced Proteome Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Intrinsic Value: Projected FCF Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -0.35 -0.40 -0.21 -0.12

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.12 -0.41 -0.51 -0.64

Competitive Comparison of Advanced Proteome Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Price-to-Projected-FCF falls into.



Advanced Proteome Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Advanced Proteome Therapeutics's Free Cash Flow(6 year avg) = $-0.86.

Advanced Proteome Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Apr23)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-0.85984+-0.022/0.8)/40.711
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Proteome Therapeutics  (OTCPK:APTCF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Advanced Proteome Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0002/-0.20175085643375
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Proteome Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines